Real-world progression in the survival of de novo Metastatic prostate cancer over the past decade

前列腺癌 医学 比例危险模型 内科学 相对存活率 总体生存率 肿瘤科 生存分析 癌症 多元分析 转移 癌症登记处
作者
Xiaoxiao Guo,Haoran Xia,Fengbo Zhang,Gangyue Hao
出处
期刊:Urologic Oncology-seminars and Original Investigations [Elsevier BV]
标识
DOI:10.1016/j.urolonc.2023.11.021
摘要

The impact of evolving treatment strategies for metastatic prostate cancer (mPCa) on real-world survival is not well understood. We analyzed changes in mPCa survival over the past decade and discussed the potential driving factors behind these changes. Our study involved 43,228 mPCa patients (2004–2020) from the SEER database, divided into 4 diagnostic periods. We used a multivariate Cox proportional hazards model to evaluate diagnostic periods' influence on overall mortality (OM) and prostate cancer-specific mortality (PSM), and calculated relative median survival improvements between adjacent periods. Subgroup analyses based on age and distant metastasis sites were conducted. Patients diagnosed in 2016 to 2020 experienced significantly reduced mortality risk compared to those in 2004 to 2007 (HR 0.64 for OM, HR 0.62 for CSM, both P < 0.001). The study period witnessed an absolute improvement in median overall survival (OS) and prostate cancer-specific survival (PCSS), 17 months (54.8%) and 25 months (67.6%) respectively. The most rapid relative survival improvement occurred post-2016, with a 29.7% increase in median OS and a 37.8% increase in PCSS compared to 2012 to 2015. There was a significant reduction in mortality risk throughout the study period in both age groups (age <75 and ≥75), but absolute survival gains were smaller in the older group (24 months [68.6%] vs. 8 months [32%] for OS, 36 months [90.0%] vs. 11 months [33.3%] for PCSS), with lower relative survival improvements after 2016 (37.2% vs. 17.9% for OS, 49% vs. 22.2% for PCSS). All metastasis site subgroups (except M1a) exhibited a significant reduction in mortality risk (all P < 0.001). Absolute survival improvements were 58 months (134.9%) for M1a, 16 months (50.0%) for M1b, and 17 months (54.8%) for M1c. The survival of mPCa have significantly improved over the past decade, although the progress is slower in elderly patients. Investigating the underlying reasons for survival differences among various patient profiles can further refine mPCa treatment strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lemrain完成签到 ,获得积分10
刚刚
cq_2完成签到,获得积分10
10秒前
飞龙在天完成签到,获得积分0
10秒前
虚心的不二完成签到 ,获得积分10
10秒前
少管我完成签到 ,获得积分10
10秒前
小雨发布了新的文献求助10
11秒前
xin_you完成签到,获得积分10
12秒前
毛豆爸爸完成签到,获得积分0
14秒前
15秒前
YamDaamCaa应助科研通管家采纳,获得30
19秒前
欢呼的飞荷完成签到 ,获得积分10
20秒前
24秒前
康复小白完成签到 ,获得积分10
26秒前
nano完成签到 ,获得积分10
27秒前
耍酷的剑身完成签到,获得积分10
32秒前
34秒前
37秒前
热心的棒棒糖完成签到,获得积分10
37秒前
40秒前
40秒前
Cliu1981发布了新的文献求助10
44秒前
沐紫心完成签到 ,获得积分10
45秒前
LJJ完成签到 ,获得积分10
48秒前
桢桢树完成签到 ,获得积分10
48秒前
gdgd完成签到,获得积分10
51秒前
51秒前
lshchoo发布了新的文献求助10
57秒前
58秒前
YamDaamCaa完成签到,获得积分10
58秒前
贾方硕完成签到,获得积分10
1分钟前
153266916完成签到 ,获得积分10
1分钟前
冰阔落完成签到 ,获得积分10
1分钟前
七七完成签到 ,获得积分10
1分钟前
小花小宝和阿飞完成签到 ,获得积分10
1分钟前
端庄代荷完成签到 ,获得积分10
1分钟前
lshchoo完成签到,获得积分10
1分钟前
传奇3应助漂亮的忆文采纳,获得10
1分钟前
ivy完成签到 ,获得积分10
1分钟前
1分钟前
ken131完成签到 ,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167370
捐赠科研通 3248804
什么是DOI,文献DOI怎么找? 1794465
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664